MedTrace Logo

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

NCT00398086 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2019-11-22

Study results available
· View outcomes & findings →

Summary

To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine

Administered by intravenous infusion over 30 minutes.

DRUG

Albumin-bound paclitaxel

Administered by intravenous infusion over 30 minutes.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Daniel Von Hoff, MD · Scottsdale Clinical Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-01
Primary Completion
2008-09-01
Completion
2010-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398086 on ClinicalTrials.gov